Precigen Sees Unusually Large Options Volume (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) saw some unusual options trading on Thursday. Investors acquired 11,169 call options on the company. This represents an increase of 1,645% compared to the typical volume of 640 call options.

Precigen Stock Performance

NASDAQ PGEN opened at $1.34 on Friday. The stock has a market capitalization of $392.45 million, a price-to-earnings ratio of -2.44 and a beta of 1.65. The stock’s 50 day moving average price is $0.93 and its two-hundred day moving average price is $1.06. Precigen has a 52 week low of $0.65 and a 52 week high of $1.93.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on PGEN shares. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Precigen in a research report on Thursday. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, Precigen currently has an average rating of “Hold” and a consensus price target of $7.00.

Institutional Investors Weigh In On Precigen

Several institutional investors have recently bought and sold shares of PGEN. Traphagen Investment Advisors LLC acquired a new position in shares of Precigen during the 3rd quarter worth approximately $29,000. Stifel Financial Corp grew its holdings in Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares in the last quarter. SG Americas Securities LLC grew its holdings in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 13,823 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Precigen by 86.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 25,681 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 18,097 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.